Modality
ADC
MOA
SGLT2i
Target
SGLT2
Pathway
Amyloid
AngelmanSchizophreniaDLBCL
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
~Aug 2020
→ ~Nov 2021
NDA/BLA
Feb 2022
→ Jan 2031
NDA/BLACurrent
NCT05956737
1,580 pts·Angelman
2022-02→2031-01·Completed
1,580 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-024.8y awayPh3 Readout· Angelman
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2031-01-02 · 4.8y away
Angelman
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05956737 | NDA/BLA | Angelman | Completed | 1580 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |